Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: suvorexant Clear all
Completed Phase 4 Interventional Results available

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

NCT05593653
View directory record Official record
Conditions
Insomnia, Metabolic Health, Menopause
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Terminated Phase 2 Interventional

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

NCT04262193
View directory record Official record
Conditions
Opioid-use Disorder, Sleep
Interventions
Suvorexant, Suvorexant Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 26, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sleep Trial to Prevent Alzheimer's Disease

NCT04629547
View directory record Official record
Conditions
Sleep, Alzheimer Disease
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional

Suvorexant for Treatment of AUD and PTSD

NCT06679062
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

NCT05106153
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions
Suvorexant, Zolpidem, Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 26, 2026, 2:40 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 26, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

NCT03818581
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder, Inflammation
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

NCT02729714
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Burdick, Daniel, M.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 4 Interventional

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

NCT04014387
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Not listed Phase 4 Interventional

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

NCT03412591
View directory record Official record
Conditions
Sleep Disturbance, Craving, Cortisol; Hypersecretion
Interventions
Suvorexant 20 mg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 26, 2026, 2:40 PM EDT
Recruiting Phase 4 Interventional

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

NCT03642028
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 26, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Suvorexant for Sleep in Children With Autism

NCT05546554
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use

NCT02785406
View directory record Official record
Conditions
Cocaine Use Disorder, Anxiety
Interventions
suvorexant, Placebo (for suvorexant)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

NCT03034018
View directory record Official record
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Early Phase 1 Interventional Results available

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

NCT05656534
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

The Role of Orexin in Human Panic Disorder

NCT02593682
View directory record Official record
Conditions
Panic Disorder
Interventions
suvorexant, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

NCT03657355
View directory record Official record
Conditions
Healthy Recreational Drug Users
Interventions
ACT-541468, Suvorexant, Zolpidem, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Targeting Orexin to Treat Nicotine Dependence

NCT03999099
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Suvorexant 20 mg, Suvorexant 10 mg, Placebo oral tablet
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 26, 2026, 2:40 PM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
View directory record Official record
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 26, 2026, 2:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Suvorexant and Cocaine

NCT03937986
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Suvorexant, Cocaine, Placebo oral capsule
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 26, 2026, 2:40 PM EDT